Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05823012 · ClinicalTrials.gov registry record · Phase 2
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
A Phase 2 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT05823012 is a Phase 2 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT05823012, a Phase 2 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous injections. This study includes the following periods: Screening, Titration Period, and Maintenance Period. The study will conclude with an End of Maintenance Visit or Early Termination (ET) Visit.
Interventions
- DRUG levothyroxine sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05823012
The ClinicalTrials.gov registry entry for NCT05823012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which levothyroxine sodium is the first listed.
NCT05823012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05823012 about?
NCT05823012 is a clinical study titled "Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism". This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of X...
What is the current status of trial NCT05823012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2023-05-15. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT05823012?
The interventions under investigation include: levothyroxine sodium (DRUG).
Who is sponsoring clinical trial NCT05823012?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.